CN1867355A - 包含诱导粘膜免疫的佐剂的新型疫苗 - Google Patents
包含诱导粘膜免疫的佐剂的新型疫苗 Download PDFInfo
- Publication number
- CN1867355A CN1867355A CNA2004800298053A CN200480029805A CN1867355A CN 1867355 A CN1867355 A CN 1867355A CN A2004800298053 A CNA2004800298053 A CN A2004800298053A CN 200480029805 A CN200480029805 A CN 200480029805A CN 1867355 A CN1867355 A CN 1867355A
- Authority
- CN
- China
- Prior art keywords
- vaccine
- virus
- poly
- double
- stranded rna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/099—Bordetella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A61K39/25—Varicella-zoster virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- AIDS & HIV (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
疫苗 | 攻击(40LD50) | 肺部病毒滴度(PFU/ml;10n) | 存活的小鼠/总的小鼠 | |||
一次 | 二次 | |||||
PR8(μg) | Poly(I:C)(μg) | PR8(μg) | Poly(I:C)(μg) | |||
11111- | 101031CTB*- | 11111- | 10---CTB*- | A/PR8A/PR8A/PR8A/PR8A/PR8A/PR8 | <0*N.D.N.D.N.D.<0*6.2±5.4 | 5/55/55/55/55/50/5 |
Claims (22)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP291879/2003 | 2003-08-11 | ||
JP2003291879 | 2003-08-11 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2013100494346A Division CN103446582A (zh) | 2003-08-11 | 2004-08-10 | 包含诱导粘膜免疫的佐剂的新型疫苗 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1867355A true CN1867355A (zh) | 2006-11-22 |
Family
ID=34131682
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2004800298053A Pending CN1867355A (zh) | 2003-08-11 | 2004-08-10 | 包含诱导粘膜免疫的佐剂的新型疫苗 |
CN2013100494346A Pending CN103446582A (zh) | 2003-08-11 | 2004-08-10 | 包含诱导粘膜免疫的佐剂的新型疫苗 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2013100494346A Pending CN103446582A (zh) | 2003-08-11 | 2004-08-10 | 包含诱导粘膜免疫的佐剂的新型疫苗 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20070219149A1 (zh) |
EP (1) | EP1666059A4 (zh) |
JP (1) | JP4817625B2 (zh) |
KR (1) | KR101280094B1 (zh) |
CN (2) | CN1867355A (zh) |
AU (1) | AU2004263037B2 (zh) |
RU (1) | RU2390351C2 (zh) |
WO (1) | WO2005014038A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108992667A (zh) * | 2018-08-09 | 2018-12-14 | 安徽智飞龙科马生物制药有限公司 | 一种带状疱疹疫苗及其制备方法、应用 |
WO2021155846A1 (zh) * | 2020-02-05 | 2021-08-12 | 翁炳焕 | 一种新型冠状病毒肺炎双价疫苗的制备方法 |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1898948B1 (en) | 2005-06-08 | 2012-01-04 | Yisheng Biopharma (Singapore) Pte. Ltd. | Polyinosinic acid-polycytidylic acid-based adjuvant |
US20080233105A1 (en) * | 2005-09-13 | 2008-09-25 | Green William R | Compositions and methods for preventing or treating a viral infection |
JP4828189B2 (ja) * | 2005-09-14 | 2011-11-30 | 雅美 森山 | 分泌型IgA及びIgG抗体誘導剤 |
US7943147B2 (en) | 2005-12-07 | 2011-05-17 | Hemispherx Biopharma | dsRNAs as influenza virus vaccine adjuvants or immuno-stimulants |
US20070166800A1 (en) | 2006-01-13 | 2007-07-19 | Haixiang Lin | Immunogenic substances comprising a polyinosinic acid-polycytidilic acid based adjuvant |
KR101273836B1 (ko) * | 2006-02-28 | 2013-06-11 | 박사르트, 인크. | 키메라 아데노바이러스 벡터 |
MX2009008926A (es) * | 2007-02-23 | 2009-09-14 | Baylor Res Inst | Aplicaciones terapeuticas de activacion de celulas que presentan antigeno humano por medio de detectina a-1. |
JP2009209086A (ja) * | 2008-03-04 | 2009-09-17 | Masami Moriyama | 粘膜投与型ワクチン |
US8871207B2 (en) | 2008-07-25 | 2014-10-28 | Humabs, LLC | Neutralizing anti-influenza A virus antibodies and uses thereof |
AU2009275227A1 (en) * | 2008-07-25 | 2010-01-28 | Institute For Research In Biomedicine | Neutralizing anti-influenza a virus antibodies and uses thereof |
CN102281892A (zh) * | 2009-01-13 | 2011-12-14 | 特朗斯吉有限公司 | 酿酒酵母线粒体核酸级分用于免疫刺激的用途 |
US9603919B2 (en) | 2009-03-31 | 2017-03-28 | Japan As Represented By The Director-General Of National Institute Of Infectious Diseases | Method for prophylaxis of influenza using vaccine for intranasal administration |
JP2011057605A (ja) * | 2009-09-09 | 2011-03-24 | Masami Moriyama | 粘膜投与型ワクチン |
DK2689016T3 (en) * | 2011-03-22 | 2015-04-27 | Mucosis Bv | Immunogenic formations in particle form and fremgangmsåder for the production thereof |
HUE051756T2 (hu) | 2011-07-18 | 2021-03-29 | Inst Res Biomedicine | Influenza A vírus elleni semlegesítõ antitestek és alkalmazásuk |
US9844592B2 (en) * | 2011-07-18 | 2017-12-19 | Icahn School Of Medicine At Mount Sinai | Bacterial RNAs as vaccine adjuvants |
US20130039973A1 (en) * | 2011-08-03 | 2013-02-14 | Henry J. Smith | Viral Immunogenic Compositions |
EP2846767B1 (en) | 2012-05-03 | 2022-01-26 | Janssen Sciences Ireland Unlimited Company | Polyinosinic-polycytidylic acid (poly (i:c)) formulations for the treatment of upper respiratory tract infections |
CN104379170B (zh) | 2012-06-20 | 2017-05-03 | 国立大学法人东京大学 | 粘膜免疫刺激剂及hpv感染症治疗用经口药物组合物 |
TW201427687A (zh) | 2012-12-04 | 2014-07-16 | Daiichi Sankyo Co Ltd | 黏膜疫苗用佐劑 |
EP2742952A1 (en) * | 2012-12-17 | 2014-06-18 | Eurocine Vaccines AB | Influenza vaccine composition |
ES2837392T3 (es) | 2013-10-02 | 2021-06-30 | Medimmune Llc | Anticuerpos anti-influenza A neutralizantes y usos de los mismos |
US10226529B2 (en) | 2014-06-04 | 2019-03-12 | Osaka University | Adjuvant for mucosal vaccine |
CA2954780A1 (en) | 2014-07-15 | 2016-01-21 | Medimmune, Llc | Neutralizing anti-influenza b antibodies and uses thereof |
MX2017015189A (es) | 2015-06-01 | 2018-04-13 | Medimmune Llc | Neutralizacion de moleculas de union anti-influenza y usos de las mismas. |
WO2017123685A1 (en) | 2016-01-13 | 2017-07-20 | Medimmune, Llc | Method of treating influenza a |
JP2017086068A (ja) * | 2016-10-31 | 2017-05-25 | インスティテュート・フォー・リサーチ・イン・バイオメディシンInstitute For Research In Biomedicine | A型インフルエンザウイルス中和抗体及びその使用法 |
JP2020050605A (ja) | 2018-09-26 | 2020-04-02 | デンカ生研株式会社 | 粘膜アジュバント |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3906092A (en) * | 1971-11-26 | 1975-09-16 | Merck & Co Inc | Stimulation of antibody response |
US4024222A (en) * | 1973-10-30 | 1977-05-17 | The Johns Hopkins University | Nucleic acid complexes |
US6130206A (en) * | 1980-07-07 | 2000-10-10 | Hem Research, Inc. | Treating viral infections associated with chronic fatigue with dsRNA |
US5063209A (en) * | 1985-08-26 | 1991-11-05 | Hem Research, Inc. | Modulation of aids virus-related events by double-stranded RNAs |
US4795744A (en) * | 1986-07-17 | 1989-01-03 | Hem Research, Inc. | Modulation of AIDS virus-related events by double-stranded RNAS |
US4820696A (en) * | 1985-08-26 | 1989-04-11 | Hem Research, Inc. | Modulation of aids virus-related events by double-stranded RNAS |
US4945082A (en) * | 1985-08-26 | 1990-07-31 | Hem Research, Inc. | Controlled dsRNA therapy for human viral infections |
US5298614A (en) * | 1986-01-06 | 1994-03-29 | Nippon Shinyaku Co. Ltd. | Size limited double stranded poly I poly(cytidylate/4-thiouridylate) |
US4950652A (en) * | 1987-03-23 | 1990-08-21 | Hem Research, Inc. | dsRNAs for combination therapy in the treatment of viral diseases |
JPH01238597A (ja) * | 1987-07-03 | 1989-09-22 | Nippon Shinyaku Co Ltd | 核酸誘導体 |
US5091374A (en) * | 1987-07-17 | 1992-02-25 | Hem Research Inc. | Double-stranded RNA correction of abnormalities in circulating immune complexes and monocyte function |
US5906980A (en) * | 1987-07-17 | 1999-05-25 | Hem Research Inc. | Treatment of hepatitis with mismatched dsRNA |
US5712257A (en) * | 1987-08-12 | 1998-01-27 | Hem Research, Inc. | Topically active compositions of mismatched dsRNAs |
US4963532A (en) * | 1987-11-25 | 1990-10-16 | Hem Research, Inc. | dsRNA-based prevention of viral escape |
US5194245A (en) * | 1990-05-25 | 1993-03-16 | Hem Research Inc. | Diagnosis of viral hepatitis |
US5840565A (en) * | 1995-08-22 | 1998-11-24 | The Regents Of The University Of California | Methods for enhancing the production of viral vaccines in PKR-deficient cell culture |
US5919480A (en) * | 1996-06-24 | 1999-07-06 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Liposomal influenza vaccine composition and method |
IL139813A0 (en) * | 1998-05-22 | 2002-02-10 | Loeb Health Res Inst At The Ot | Methods and products for inducing mucosal immunity |
WO2000020039A1 (en) * | 1998-10-05 | 2000-04-13 | The Regents Of The University Of California | Methods and adjuvants for stimulating mucosal immunity |
US6589529B1 (en) * | 1998-10-30 | 2003-07-08 | Children's Hospital Medical Center | Rotavirus subunit vaccine |
DE60022665T2 (de) * | 1999-09-25 | 2006-06-22 | Coley Pharmaceutical Gmbh | Immunstimulierende nukeinsäuren |
AU2002361468A1 (en) * | 2001-08-14 | 2003-03-18 | The Government Of The United States Of America As Represented By The Secretary Of Health And Human S | Method for rapid generation of mature dendritic cells |
AU2002358616A1 (en) * | 2001-12-07 | 2003-06-17 | Intercell Ag | Immunostimulatory oligodeoxynucleotides |
JP2007524615A (ja) * | 2003-06-20 | 2007-08-30 | コーリー ファーマシューティカル ゲーエムベーハー | 低分子トール様レセプター(tlr)アンタゴニスト |
-
2004
- 2004-08-10 US US10/567,766 patent/US20070219149A1/en not_active Abandoned
- 2004-08-10 KR KR1020067002870A patent/KR101280094B1/ko active IP Right Grant
- 2004-08-10 EP EP04771475A patent/EP1666059A4/en not_active Withdrawn
- 2004-08-10 WO PCT/JP2004/011488 patent/WO2005014038A1/ja active Application Filing
- 2004-08-10 AU AU2004263037A patent/AU2004263037B2/en not_active Ceased
- 2004-08-10 JP JP2004233896A patent/JP4817625B2/ja active Active
- 2004-08-10 CN CNA2004800298053A patent/CN1867355A/zh active Pending
- 2004-08-10 CN CN2013100494346A patent/CN103446582A/zh active Pending
- 2004-08-10 RU RU2006107537/13A patent/RU2390351C2/ru active
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108992667A (zh) * | 2018-08-09 | 2018-12-14 | 安徽智飞龙科马生物制药有限公司 | 一种带状疱疹疫苗及其制备方法、应用 |
WO2021155846A1 (zh) * | 2020-02-05 | 2021-08-12 | 翁炳焕 | 一种新型冠状病毒肺炎双价疫苗的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
EP1666059A1 (en) | 2006-06-07 |
AU2004263037B2 (en) | 2011-02-10 |
RU2006107537A (ru) | 2007-09-20 |
JP4817625B2 (ja) | 2011-11-16 |
CN103446582A (zh) | 2013-12-18 |
AU2004263037A1 (en) | 2005-02-17 |
US20070219149A1 (en) | 2007-09-20 |
RU2390351C2 (ru) | 2010-05-27 |
WO2005014038A1 (ja) | 2005-02-17 |
KR101280094B1 (ko) | 2013-06-28 |
EP1666059A4 (en) | 2008-08-27 |
KR20060115345A (ko) | 2006-11-08 |
JP2005097267A (ja) | 2005-04-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1867355A (zh) | 包含诱导粘膜免疫的佐剂的新型疫苗 | |
JP6826027B2 (ja) | インフルエンザ抗原送達用のベクターおよび構築体 | |
JP3608642B2 (ja) | 核酸製剤 | |
ES2858315T3 (es) | Proteína F de prefusión de VRS soluble estabilizada para uso en la profilaxis de la infección por VRS | |
Krammer et al. | Alternative influenza vaccines made by insect cells | |
CN1285608C (zh) | 副流感病毒糖蛋白和疫苗 | |
CN1391463A (zh) | 鼻内流感病毒疫苗 | |
ZA200509187B (en) | DNA vaccine expressing HA 1 of equine-2 influenza virus | |
US11389523B2 (en) | Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (HA) protein | |
KR20140127827A (ko) | H3n2, h2n2, 및 b 인플루엔자 바이러스에 대한 계산적으로 최적화된 넓게 반응하는 항원 | |
EP2525818A2 (en) | Immunogenic influenza composition | |
JP5343079B2 (ja) | トリインフルエンザウイルス抗原及び経口投与で有効な粘膜アジュバントを併用したトリインフルエンザワクチンの追加免疫方法 | |
JP2023534840A (ja) | M2/bm2欠失インフルエンザベクターを使用したワクチン | |
Sączyńska et al. | A novel hemagglutinin protein produced in bacteria protects chickens against H5N1 highly pathogenic avian influenza viruses by inducing H5 subtype-specific neutralizing antibodies | |
RU2358981C2 (ru) | Универсальная вакцина против вируса гриппа птиц | |
CN1124013A (zh) | 含3-邻位-脱酰基的单磷酰基脂质a的流感疫苗组合物 | |
US20210379180A1 (en) | Broadly reactive immunogens of influenza h3 virus, compositions and methods of use thereof | |
KR20120131725A (ko) | 고병원성 조류인플루엔자 a h5n1 바이러스 유사입자 및 이를 이용한 가금용 백신 | |
CN1245217C (zh) | 一种包含dna疫苗和灭活狂犬病毒的疫苗制剂 | |
KR20190039065A (ko) | 조작된 인플루엔자 헤마글루티닌 폴리펩티드의 변형 | |
JP4031478B2 (ja) | インフルエンザ血球凝集素多価ワクチンの製造方法 | |
US20240100148A1 (en) | Broadly reactive viral antigens as immunogens, compositions and methods of use thereof | |
US20230055468A1 (en) | Broadly reactive viral antigens as immunogens, compositions and methods of use thereof | |
JP2011088864A (ja) | インフルエンザウイルスに対するベクターワクチン | |
KR102098585B1 (ko) | 교차 면역원성을 갖는 h2 아형 인플루엔자 바이러스 및 이를 포함하는 백신 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20070119 Address after: Osaka Japan Applicant after: The Research Foundation for Microbial Diseases of Osaka University Co-applicant after: Japan National Institute of Infectious Diseases Co-applicant after: epidemic prevention health company Address before: Osaka Japan Applicant before: The Research Foundation for Microbial Diseases of Osaka University Co-applicant before: Japan National Institute of Infectious Diseases Co-applicant before: Toray Industries, Inc. |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1098690 Country of ref document: HK |
|
C12 | Rejection of a patent application after its publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20061122 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1098690 Country of ref document: HK |